Licensing and Registration of Toy Establishments

Ask AI

FDA CIRCULAR NO. 2013-029: Licensing and Registration of Toy Establishments

Getting related questions...
What do you want to know about the law?
Your conversations and searches stay on your device. We do not store or track your activity on our servers. To know more about our privacy commitment see jur.ph/privacy Ask AI provides quick answers grounded in full case texts to avoid mistakes. Always verify with the original text.

Ask AI

Title Supreme Court: Licensing and Registration of Toy Establishments

Law: Fda Circular No. 2013-029

Decision Date: Dec 27, 2013

Effective January 2, 2014, the regulation of toys and childcare articles, including infant bottles and sippy cups, has been transferred to the Center for Cosmetics Regulation and Research, requiring all toy manufacturing and distribution establishments to adhere to new licensing and registration procedures through the FDA-PAIR Unit.

administrative law

A

Scope of Regulated Products and Establishments

All establishments engaged in the manufacturing and distribution of toys are included under the regulation of the CCRR.
This encompasses all toys intended for children as well as childcare articles such as infant bottles and sippy cups.

Licensing and Registration Procedures

Establishments must file their applications for licensing of toy establishments and registration of toy products through the FDA-Public Assistance, Information and Receiving (PAIR) Unit.
The existing procedures implemented by the PAIR Unit must be followed for the processing of these applications.

Access to Information and Assistance

Additional details, forms, and guidance materials are made available on the FDA website under "Industry Corner" > "Downloadables" > "Public Assistance, Information and Receiving (PAIR)".
For inquiries and further assistance, the FDA provides contact options including a landline telephone number (857-1984) and email address (info@fda.gov.ph).

Administrative Oversight

The circular was issued under the authority of the Acting Director General of the FDA, Dr. Kenneth Y. Hartigan-Go, affirming the administrative direction and enforcement of these new regulatory arrangements.

END